Eskin Maxim, Eurich Dean T, Simpson Scot H
Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD), University of Alberta.
School of Public Health, University of Alberta, Edmonton, AB, Canada, T6G 2G3;.
J Popul Ther Clin Pharmacol. 2018 Mar 20;25(1):e39-e52. doi: 10.22374/1710-6222.25.1.4.
BACKGROUND - A variety of methods are used to define exposure in pharmacoepidemiologic studies. Although each method has known biases, the relative effect of these biases on an observed association has not been fully examined. OBJECTIVE - To explore the influence of different exposure definitions on estimates, using the association between metformin and all-cause mortality as a proto-typical model. METHODS - New users of oral anti-hyperglycemic drugs were identified using administrative health databases from Alberta, Canada between 1998 and 2010. Drug exposure was described using definitions that are commonly used in observational studies. All analyses included the same covariates of age, gender, and a comorbidity score, and subjects not exposed to metformin served as the reference group. The measure of association was assessed using a Cox Proportional Hazards model for cohort studies and conditional logistic regression for case-control studies. RESULTS - We identified 64,293 new oral anti-hyperglycemic drugs users; mean age 68.9 years, 33,131 (52%) males, and 24,745 (39%) deaths during a mean follow-up of 6 years. In adjusted models, the association between metformin and mortality ranged from 0.23 (95% CI 0.22-0.25) to 0.92 (95% CI 0.88-0.95) reduction. Most metformin exposure definitions, however, provided estimates in the 0.6-0.8 reduction range, aligning with the results of previous observational studies. CONCLUSIONS - The variety of exposure definitions tested in this analysis produced a wide range of associations between metformin and mortality risk. Therefore, pharmacoepidemiological studies should implement sensitivity analyses including at least two exposure definitions to provide more robust and potentially valid study estimates.
背景——在药物流行病学研究中,有多种方法用于定义暴露。尽管每种方法都存在已知的偏倚,但这些偏倚对观察到的关联的相对影响尚未得到充分研究。目的——以二甲双胍与全因死亡率之间的关联作为典型模型,探讨不同暴露定义对估计值的影响。方法——利用加拿大艾伯塔省1998年至2010年的行政卫生数据库,确定口服降糖药的新使用者。使用观察性研究中常用的定义来描述药物暴露情况。所有分析都纳入了相同的年龄、性别和合并症评分协变量,未暴露于二甲双胍的受试者作为参照组。采用队列研究的Cox比例风险模型和病例对照研究的条件逻辑回归来评估关联度。结果——我们确定了64,293名口服降糖药新使用者;平均年龄68.9岁,男性33,131名(52%),在平均6年的随访期间有24,745名(39%)死亡。在调整模型中,二甲双胍与死亡率之间的关联降低幅度从0.23(95%置信区间0.22 - 0.25)到0.92(95%置信区间0.88 - 0.95)不等。然而,大多数二甲双胍暴露定义得出的降低幅度估计值在0.6 - 0.8范围内,与先前观察性研究的结果一致。结论——本分析中测试的多种暴露定义导致二甲双胍与死亡风险之间产生了广泛范围的关联。因此,药物流行病学研究应进行敏感性分析,至少包括两种暴露定义,以提供更可靠且可能有效的研究估计值。